Abstract | AIMS: METHODS: A retrospective analysis of 39 consecutive patients who underwent reduction hepatectomy followed by TACE for advanced T-Staged HCCs was undertaken. RESULTS: Reduction hepatectomies, including 20 major ones, were performed. After a median interval of 30 days, the hepatectomies were followed by TACE using farmorubicin. Actual overall 3-year survival after surgery was 32%. Indocyanine green R(15) > or =15%, preoperative AFP > or =2000 ng/ml, and tumour reduction rate <98% were predictive of decreased overall survival. When the three prognostic factors were used in a scoring system, with one point assigned for each factor, the 3-year survival rates of patients with scores of 0, 1, 2, and 3 were 71%, 40%, 0%, and 0% respectively. CONCLUSIONS: Reduction hepatectomy followed by TACE is effective in patients with advanced T-Staged HCCs who have none of the 3 poor prognostic factors. Reduction surgery followed by TACE is one of the options for controlling advanced T-Staged HCCs in patients who are not candidates for curative resection or TACE alone.
|
Authors | A Kobayashi, S Takahashi, H Ishii, M Konishi, T Nakagohri, N Gotohda, M Satake, J Furuse, T Kinoshita |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 33
Issue 8
Pg. 1019-24
(Oct 2007)
ISSN: 0748-7983 [Print] England |
PMID | 17399939
(Publication Type: Journal Article)
|
Chemical References |
- alpha-Fetoproteins
- Epirubicin
|
Topics |
- Adult
- Aged
- Carcinoma, Hepatocellular
(pathology, surgery, therapy)
- Chemoembolization, Therapeutic
- Chemotherapy, Adjuvant
- Epirubicin
(administration & dosage)
- Female
- Hepatectomy
(methods)
- Humans
- Liver Neoplasms
(pathology, surgery, therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Retrospective Studies
- Survival Rate
- Treatment Outcome
- alpha-Fetoproteins
(analysis)
|